 BP2 is a novel beta-lactam-derived beta-lactamase inhibitor that can be used in combination with meropenum to treat virulent enterobacterial strains expressing serine and metalo-beta-lactamases, MBLs. It has been shown to be effective in reducing the number of pathogenic bacteria in a mouse model, suggesting it could be a viable option for treating resistant infections caused by MBLs. This article was authored by Nikita Reddy, Latisha Gurdari, Banjini Shungub, and others.